Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam preconditioning during cardiopulmonary bypass cardiac surgery
ChiCTR2200065352Phase 4Not yet recruiting
- Sponsor
- The Affiliated Hospital of Guangdong Medical University
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remimazolam in Systemic Inflammatory Response Syndrome (SIRS) (2 arms), sponsored by The Affiliated Hospital of Guangdong Medical University. Primary endpoint: White blood cell count. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
remimazolam
03
Conditions
Systemic Inflammatory Response Syndrome (SIRS)
Beyond the preview
Go deeper on ChiCTR2200065352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065352.